4.6 Article

Examining the Relationship between Circulating CD4-CD8-Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma

期刊

CELLS
卷 10, 期 2, 页码 -

出版社

MDPI
DOI: 10.3390/cells10020406

关键词

double negative T cells; checkpoint inhibitors; melanoma; immunotherapy resistance

向作者/读者索取更多资源

The study investigated the role of circulating CD4-/CD8- double-negative T cells (DNTs) in the immune response to melanoma in patients treated with checkpoint blockade. Results showed that better treatment outcomes were associated with certain clinical features and immune cell levels, such as normal LDH levels, fewer metastatic sites, and higher lymphocyte counts. The decrease in DNT cells and increase in lymphocyte count were significantly correlated with achieving an overall response to treatment.
Background: The role of circulating CD4-/CD8- double-negative T cells (DNTs) in the immune response to melanoma is poorly understood, as are the effects of checkpoint inhibitors on T cell subpopulations. Methods: We performed a basal and longitudinal assessment of circulating immune cells, including DNTs, in metastatic melanoma patients treated with checkpoint blockade in a single-center cohort, and examined the correlations levels of immune cells with clinical features and therapy outcomes. Results: Sixty-eight patients (48 ipilimumab, 20 PD1 inhibitors) were enrolled in the study. Our analysis indicated that better outcomes were associated with normal LDH, fewer than three metastatic sites, an ECOG performance status of 0, M1a stage, lower WBC and a higher lymphocyte count. The increase in lymphocyte count and decrease of DNTs were significantly associated with the achievement of an overall response. The median value of DNT decreased while the CD4+ and NK cells increased in patients that responded to treatment compare to those who did not respond to treatment. Conclusions: DNT cells change during treatment with checkpoint inhibitors and may be adept at sensing the immune response to melanoma. The complementary variation of DNT cells with respect to CD4+ and other immune actors may improve the reliability of lymphocyte assessment. Further investigation of DNT as a potential target in checkpoint inhibitor resistant melanoma is warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据